Sucampo built a foundation on the therapeutic power of prostones. Our work in this area has helped us create a proven blueprint for identifying, developing and commercializing treatments and innovative pharmaceuticals.
Today, we are evolving our focus to include new and exciting areas of science and medicine. We remain committed to investing in the development of new compounds and novel applications, while at the same time relentlessly pursuing additional partnerships that can help us positively impact other health issues.
The therapeutic potential of prostones was first discovered by our co-founder, Dr. Ryuji Ueno, and under his leadership, Sucampo became a pioneer in the field.
Prostones are naturally-occurring fatty acid metabolites which originally were thought to be biologically inactive and have now emerged as a promising compound class with physiological activities that can be targeted for the treatment of unmet or underserved medical needs.
Prostones are believed to act locally to restore normal function in cells and tissues, and hence, their pharmacologic activity may be targeted to specific organs and tissues. They are believed to possess a mechanism of action as highly potent and selective ion channel activators based on in vitro studies and are physiological mediators that may have a role in the restoration of cellular homeostasis and tissue regeneration.
Sucampo’s work in the area of prostones led to the development of an approved pharmaceutical product.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.